These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 20823825)

  • 61. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
    Pediatric OCD Treatment Study (POTS) Team
    JAMA; 2004 Oct; 292(16):1969-76. PubMed ID: 15507582
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inability to cry during SRI treatment.
    Oleshansky MA; Labbate LA
    J Clin Psychiatry; 1996 Dec; 57(12):593. PubMed ID: 9010124
    [No Abstract]   [Full Text] [Related]  

  • 63. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.
    Greist JH; Jefferson JW; Kobak KA; Chouinard G; DuBoff E; Halaris A; Kim SW; Koran L; Liebowtiz MR; Lydiard B
    Int Clin Psychopharmacol; 1995 Jun; 10(2):57-65. PubMed ID: 7673657
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dose-Dependent Urinary Incontinence with Sertraline Use in Obsessive-Compulsive Disorder.
    Pease E; Singh B; Ziegelmann M; Betcher H
    Psychopharmacol Bull; 2021 Nov; 51(4):117-121. PubMed ID: 34887603
    [No Abstract]   [Full Text] [Related]  

  • 65. Intermittent Electric Shock-Like Sensations Associated With Sertraline Use for Treatment of Obsessive-Compulsive Disorder.
    Viani I; Meyer F
    J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):101-103. PubMed ID: 34928566
    [No Abstract]   [Full Text] [Related]  

  • 66. Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder.
    March JS; Franklin ME; Leonard H; Garcia A; Moore P; Freeman J; Foa E
    Biol Psychiatry; 2007 Feb; 61(3):344-7. PubMed ID: 17241830
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Newer generation antidepressants for depressive disorders in children and adolescents.
    Hetrick SE; McKenzie JE; Cox GR; Simmons MB; Merry SN
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD004851. PubMed ID: 23152227
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Aripiprazole Treatment for Obsessive Compulsive Disorder in 2 Young Subjects Who Could Not Tolerate Selective Serotonin Reuptake Inhibitors (SSRIs).
    Coskun M; Karayagmurlu A
    J Clin Psychopharmacol; 2020; 40(3):310-312. PubMed ID: 32332471
    [No Abstract]   [Full Text] [Related]  

  • 69. Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder.
    Poyurovsky M; Kurs R; Weizman A
    J Clin Psychiatry; 2003 May; 64(5):611. PubMed ID: 12755669
    [No Abstract]   [Full Text] [Related]  

  • 70. Hyperpigmentation with amisulpride.
    Mendhekar DN
    Aust N Z J Psychiatry; 2009 Jan; 43(1):88. PubMed ID: 19086350
    [No Abstract]   [Full Text] [Related]  

  • 71. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies.
    Chouinard G
    Int Clin Psychopharmacol; 1992 Oct; 7 Suppl 2():37-41. PubMed ID: 1484177
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Extraordinarily fast response to low-dose sertraline in a child with severe obsessive-compulsive disorder and high functioning serotonin transporter genotype.
    Grünblatt E; Tschakarjan S; Brezinka V; Walitza S
    J Child Adolesc Psychopharmacol; 2014 Mar; 24(2):102-4. PubMed ID: 24432825
    [No Abstract]   [Full Text] [Related]  

  • 73. Prospective relationship between obsessive-compulsive and depressive symptoms during multimodal treatment in pediatric obsessive-compulsive disorder.
    Meyer JM; McNamara JP; Reid AM; Storch EA; Geffken GR; Mason DM; Murphy TK; Bussing R
    Child Psychiatry Hum Dev; 2014; 45(2):163-72. PubMed ID: 23756717
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cognitive-behavioral group therapy versus sertraline for obsessive-compulsive disorder: five-year follow-up.
    Borges CP; Meyer E; Ferrão YA; Souza FP; Sousa MB; Cordioli AV
    Psychother Psychosom; 2011; 80(4):249-50. PubMed ID: 21540627
    [No Abstract]   [Full Text] [Related]  

  • 76. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial.
    Hedayati SS; Gregg LP; Carmody T; Jain N; Toups M; Rush AJ; Toto RD; Trivedi MH
    JAMA; 2017 Nov; 318(19):1876-1890. PubMed ID: 29101402
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder.
    Lepola U; Arató M; Zhu Y; Austin C
    J Clin Psychiatry; 2003 Jun; 64(6):654-62. PubMed ID: 12823079
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.
    Hetrick S; Merry S; McKenzie J; Sindahl P; Proctor M
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004851. PubMed ID: 17636776
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial.
    Moak DH; Anton RF; Latham PK; Voronin KE; Waid RL; Durazo-Arvizu R
    J Clin Psychopharmacol; 2003 Dec; 23(6):553-62. PubMed ID: 14624185
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline?
    Zarate CA; Kando JC; Tohen M; Weiss MK; Cole JO
    J Clin Psychiatry; 1996 Feb; 57(2):67-71. PubMed ID: 8591971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.